SCHEMBL18894152

SCHEMBL18894152

Cc1cccc2c1n[c]n2O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.36
ALDH1A1 P00352 2/20 0.34
TLR8 Q9NR97 1/20 0.33
ELANE P08246 1/20 0.33
AURKA O14965 1/20 0.32
ALKBH5 Q6P6C2 1/20 0.32
FTO Q9C0B1 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HTR3A P46098 1/20 0.31
ATM Q13315 2/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
CA2 P00918 1/20 0.31
TRPA1 O75762 2/20 0.30
PARP15 Q460N3 1/20 0.30
PARP10 Q53GL7 1/20 0.30
TNKS2 Q9H2K2 1/20 0.30
PARP2 Q9UGN5 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2A6 P11509 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323208 0.78 TLR8 (0.37) ALDH1A1TLR8AURKAALKBH5FTO
SCHEMBL18894190 0.77 ALDH1A1 (0.34) ALDH1A1TLR8AURKAALKBH5FTO
SCHEMBL1826324 0.77 AURKA (0.35) ALDH1A1TLR8AURKAALKBH5FTO
SCHEMBL18894161 0.77 ALDH1A1 (0.34) DAOALDH1A1TLR8AURKAALKBH5
SCHEMBL18894154 0.75 ALDH1A1 (0.34) DAOALDH1A1TLR8AURKAKDM4E
SCHEMBL18894124 0.75 ALDH1A1 (0.32) ALDH1A1TLR8
SCHEMBL18894151 0.74 ALDH1A1 (0.33) ALDH1A1TLR8AURKAALKBH5FTO
SCHEMBL18894202 0.73 TSHR (0.33) ALDH1A1TLR8AURKAKDM4ECYP1A2
SCHEMBL18894130 0.72 ALDH1A1 (0.40) DAOALDH1A1TLR8AURKA
SCHEMBL2670682 0.71 POLB (0.48) DAOALDH1A1TLR8ELANEAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136310-B2 Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors UCB Biopharma SRL (BE) 2021-10-05 US disclosed
US-20200283416-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS CELLTECH R&D LIMITED (GB) 2020-09-10 US disclosed
EP-3380464-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS UCB Biopharma SPRL (BE) 2018-10-03 EP disclosed
WO-2017089453-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS UCB BIOPHARMA SPRL (BE) 2017-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283416-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS PEPD, ADAM17, ANPEP DAO 248/4885ALDH1A1 3365/4885TLR8 2145/4885
US-11136310-B2 Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors PEPD, ADAM17, ANPEP DAO 248/4885ALDH1A1 3365/4885TLR8 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.